Roche said it found "many shortcomings" in what it described as a "seriously flawed" review of neuraminidase inhibitors published recently in the BMJ that questioned the effectiveness of its influenza drug Tamiflu (oseltamivir), the Financial Times reported Monday. According to Daniel Thurley, Roche's medical director in the UK, researchers at The Cochrane Collaboration who conducted the study "appear not to have understood how Tamiflu works" and also failed to consider all the data available to them.